

About Zomedica

Based in Ann Arbor, Michigan, Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica's mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.

Veterinary Customers

Companion animal veterinary medicine is a unique opportunity compared to human medicine:

- **Veterinarians:** serve as both clinician and pharmacist.
- **Payers:** cost of care is often not subsidized by third-party payers, i.e. insurance.
- **Patients:** multiple species of variable sizes.
- **Pharmacy:** rely heavily on unapproved animal drugs, i.e. approved human drugs used off-label or compounded drugs.

Moreover, clinical veterinarians are dealing with compassion fatigue, margin pressures, disproportionate student debt and other factors that affect their professional and personal satisfaction. Statistics show an alarmingly high risk of suicide in the veterinary profession, possibly attributed to those challenges.

Stock Information

Exchange Ticker - FX	NYSE American: ZOM US\$	TSX-V: ZOM CDN\$
Price @ 3/01/18	\$2.10	\$2.74
52-Week Range	\$2.47 - \$1.79	\$3.25 - \$1.20
Avg. Daily Volume	20,683	2,648

Capitalization Table

Cash @ Dec. 31, 2017	\$3.4 MM
Working Capital @ Dec. 31, 2017	\$3.4 MM
Available Unsecured Loan Facility	\$5.0 MM
Common Shares @ Feb 27, 2018	
Basic	90.4 MM
Options	7.8 MM
Market Capitalization @ US\$2.10, March 1, 2018	\$199 MM

Industry
Animal health/biotechnology

Target Species
Companion animals:
cats, dogs, horses

Target Customers
Clinical veterinarians

Fiscal Year-End
December 31

Capital Stock
\$18.2 million

Number of Employees
21 FTEs

Address
100 Phoenix Drive, Ste. 190
Ann Arbor, MI 48108

Media Contact
+1 734.369.2555 Ext. 116
news@zomedica.com

Investor Relations Contact
PCG Advisory Group
+1 646.863.6519
ksmith@pcgadvisory.com



Pipeline: Novel Diagnostics + Innovative Therapeutics

Zomedica has entered into a license and supply agreement with Celsee, Inc. (“Celsee”) to develop and market Celsee’s liquid biopsy platform for application as a veterinary cancer diagnostic. Using Celsee’s liquid biopsy platform, Zomedica initially intends to develop and market ZM-017, a non-invasive diagnostic assay or blood test that helps veterinarians diagnose cancer in canines.

Zomedica’s therapeutic pipeline is based on human approved drug formulations or compounding pharmacy formulations that veterinarians are already using to treat their patients. Zomedica’s therapeutic candidates are being formulated for animal physiology, tested for safety and efficacy, and submitted to the FDA Center for Veterinary Medicine (FDA-CVM) for approval. Zomedica’s lead therapeutic candidates are identified below.



 <p>ZM-017 // canine cancer assay Cancer liquid biopsy</p>	<p>H1 2018: expect to commence clinical validation H2 2018: expect to commence marketing</p>
--	--



 <p>ZM-012 // Metronidazole Tablet Anti-diarrheal Approved for use in humans</p>	<p>H1 2018: expect to commence pivotal safety study H2 2018: expect to complete pivotal safety study</p>
--	--

 <p>ZM-007 // Metronidazole Oral Suspension Anti-diarrheal For small breeds and puppies</p>	<p>H1 2018: expect to hold pre-submission meeting with FDA-CVM</p>
---	--

 <p>ZM-006 // Transdermal Methimazole Hyperthyroidism Oral formulation approved for use in humans and cats</p>	<p>H1 2018: expect to complete pilot testing H2 2018: expect to commence and complete pivotal safety study</p>
--	--

 <p>ZM-011 // Transdermal Fluoxetine Behavioral disorders, e.g. inappropriate urination Same API as Prozac®</p>	<p>H2 2018: expect to complete pilot testing</p>
---	--

Zomedica is actively looking to expand its diagnostic pipeline through collaborations, in-licensing, and other strategic relationships involving technologies appropriate for the veterinary medicine space.